Hospital 30-day Readmission Rates in Patients with Decompensated Cirrhosis: A Nationwide Sample
AASLD LiverLearning®, George Cholankeril, 144650
Differential Access to Direct Acting Antivirals (DAAs) Across Federal, State, Commercial, and Manufacturer Patient Assistance Programs (MPAP)
AASLD LiverLearning®, Jane Giang, 144651
'Othello Hypothesis' Involved in the Development of NS5A-RAVs in Patients with Genotype 1b HCV Infection
AASLD LiverLearning®, Yoshihito Uchida, 144907
Perceptions of HCV treatment and correlates to initiation willingness in HCV+ methadone clients
AASLD LiverLearning®, Amy Jessop, 144652
Treatment of chronic HCV infection with the new direct acting antivirals (DAAs): a Real World experience in Brazil.
AASLD LiverLearning®, Hugo Cheinquer, 144908
Effectiveness and security of 3D/2D treatment in HCV/HIV coinfected cirrhotic patients
The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D±R): a large multi-center cohort
AASLD LiverLearning®, Eli Zuckerman, 144910
Efficacy and safety of Telbivudine or Tenofovir use in second to third trimester preventing vertical transmission of hepatitis B virus in real-life practice
AASLD LiverLearning®, Jinfeng Liu, 144666
Comparative Efficacy of an Intensified Re-Vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected with HIV (CORE-HIV): A Randomized Controlled Trial. Interim Analysis.
AASLD LiverLearning®, Jose Ignacio Vargas, 144667
Incidence, predictors and outcome of ventilator associated pneumonia in critically ill cirrhotics admitted to a liver intensive unit.
AASLD LiverLearning®, AMRISH SAHNEY, 144923
Early hepatitis B surface antigen seroclearance after commencement of antiviral treatment in patients with de novo HBV reactivation
AASLD LiverLearning®, Haelim Lee, 144668
Spontaneous Bacterial Peritonitis in cirrhosis: a Prospective Multicenter Study of Clinical, Microbiological characteristics and Predictors of 6 months Survival
AASLD LiverLearning®, Dimitrios Samonakis, 144924
Infection with multi-drug resistant organisms is associated with increased mortality in patients listed for liver transplantation.
AASLD LiverLearning®, Rosalie Oey, 144925
Early Fluid Resuscitation in Cirrhotic Patients Diagnosed with Severe Sepsis is Associated with Decreased In-Hospital Mortality
AASLD LiverLearning®, James Crismale, 144926
Progression to liver-related complications in HIV/hepatitis B coinfected patients in the era of potent combination antiretroviral therapy (cART) is not increased compared to hepatitis B mono-infection
AASLD LiverLearning®, Faydra Lieveld, 144682
Quantitative Hepatitis B Surface Antigen Does Not Reliably Identify Patients with Active Hepatitis D Virus Infection
AASLD LiverLearning®, Matthew Sadler, 144683
Network Approach to unveil Molecular Pathways driving Cirrhosis progression to Acute-on-Chronic Liver Failure (ACLF)
AASLD LiverLearning®, Pere Gines, 144939
Combined use of AST to platelet ratio index and Fibrosis-4 score can risk stratify hepatocellular carcinoma risk in chronic hepatitis B patients with low level viremia
AASLD LiverLearning®, Ji Hyeon Lee, 144684
Drug resistant infections in hospitalized patients with cirrhosis are nosocomial and associated with renal and respiratory failure: Results from NACSELD.
AASLD LiverLearning®, Jasmohan S. Bajaj, 144940
Improved short-term survival in patients with Acute-on-Chronic Liver Failure (ACLF) in extremis with a combination therapy approach
AASLD LiverLearning®, Gaurav Pande, 144941
Opioid use is associated with all-cause and sepsis-related death among patients with cirrhosis
AASLD LiverLearning®, Steven Scaglione, 144942
Risk for progressing to immune active (IA) phase chronic hepatitis B virus infection (CHB) among Alaska Native (AN) persons in the inactive carrier (IC) and indeterminate CHB infection phases — Alaska, 2001-2014.
AASLD LiverLearning®, Prabhu Gounder, 144698
Hepatitis B surface antigen titer is a good indicator of durable viral response after off-treatment of entecavir for chronic hepatitis B
AASLD LiverLearning®, Han ah Lee, 144699
Alcohol-related acute on chronic liver failure- comparison of various prognostic scores in predicting outcome
AASLD LiverLearning®, . Shalimar, 144955
Dynamic changes of liver stiffness predict histological reverse of liver fibrosis in chronic hepatitis B patients treated with entecavir
AASLD LiverLearning®, Yuanyuan Kong, 144700
Oral Rifaximin Soluble Solid Dispersion Immediate-Release 40 mg Prevents Development of Cirrhosis-Related Complications: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
AASLD LiverLearning®, Jasmohan S. Bajaj, 144956
Assess outcome of Slow low-dose continuous albumin,Furosemide with or without Terlipressin SIFA(T) infusion in patients of cirrhosis with refractory ascites
AASLD LiverLearning®, Gaurav Pande, 144957
Fatty acid-binding proteins (FABPs) levels are increased in decompensated cirrhosis and associated with poor outcomes
AASLD LiverLearning®, Isabel Graupera, 144958
Effect of Glucocorticoid on Hepatitis B Virus Reactivation in HBsAg-positive Rheumatoid Arthritis Patients undergoing Biologics Treatment
AASLD LiverLearning®, Yi-Hsiang Huang, 144715
Treatment of refractory ascites with the automated low-flow ascites pump: analysis of the surveillance database
AASLD LiverLearning®, Guido Stirnimann, 144971
The SNPs of HLA-DP are associated with HBsAg levels in chronic HBV infection
AASLD LiverLearning®, Ochi Yuka, 144716
Urinary NGAL biomarker predicts non response to therapy with albumin and terlipressin in patients with hepatorenal syndrome
AASLD LiverLearning®, Rafael Ximenes, 144972
Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA
AASLD LiverLearning®, Jens Verheyen, 144717
TLR-9 rs187084-dependent reduction of inflammatory and sympathetic responses to bacterial translocation in patients with decompensated cirrhosis
AASLD LiverLearning®, Paula Piñero Romero, 144973
Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis.
AASLD LiverLearning®, Troels Busk, 144974
Diagnostic performance of APRI, FIB-4 and Fibroscan for assessment of hepatic fibrosis in chronic hepatitis B patients receiving oral antiviral therapy; 7-year real life data
AASLD LiverLearning®, Iftihar Köksal, 144731
Emricasan (IDN-6556) Orally for 6 Months in Patients with Cirrhosis and Elevated MELD Score Improves Liver Function
AASLD LiverLearning®, Catherine Frenette, 144987
Validation of a Mortality Risk Score to assess the Long-Term Prognosis of Chronic Hepatitis B Patients
AASLD LiverLearning®, Willem Pieter Brouwer, 144732
Safety and efficacy of prolonged low dose thrombolysis for acute non-malignant and non-cirrhotic splanchnic venous thrombosis
AASLD LiverLearning®, Pathik Parikh, 144988
Switching to Tenofovir versus Continuing Entecavir in Chronic Hepatitis B Patients with Partial Virologic Response during Entecavir Therapy: STEEP Study
AASLD LiverLearning®, Hyung Joon Yim, 144733
The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression
AASLD LiverLearning®, Jordi Gracia-Sancho, 144989
Intrahepatic persistence of hepatitis B virus covalently closed circular DNA (cccDNA) after 3 to 5 years of telbivudine therapy for chronic hepatitis B (CHB)
AASLD LiverLearning®, Fabien Zoulim, 144747
Evaluation of Splenic Function in patients with Cirrhosis through observation of erythocytes with D.I.C. Microscopy.
AASLD LiverLearning®, Themistoklis Vasileiadis, 145003
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF)
AASLD LiverLearning®, Wan-Long Chuang, 144748
Bowel wall thickness and elasticity, Intestinal Permeability and Serum Inflammatory Mediators in Patients with Decompensated Liver Cirrhosis
AASLD LiverLearning®, Sang Hyuk Lee, 145004
Correlation of early biochemical and virologic responses during oral antiviral therapy for chronic hepatitis B
AASLD LiverLearning®, Maurizia Rossana Brunetto, 144749
Impact of Antiviral Nucleotide Analogues on Age-Dependent Decline in Renal Function
AASLD LiverLearning®, Prowpanga Udompap, 144763
A Retrospective Study on the Clearance Rate of Hepatitis B Surface Antigen with Antivirus Treatment in 1 to 7 years old Children with HBeAg-positive Chronic Hepatitis B
AASLD LiverLearning®, Zhu Shishu, 144764
A randomized trial evaluating the antiviral efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant chronic hepatitis B patients with undetectable hepatitis B virus DNA
AASLD LiverLearning®, Jang Byoung Kuk, 144765
Tenofovir disoproxil fumarate Monotherapy is superior to Entecavir-adefovir Combination in Suboptimal Responder for Lamivudine-adefovir Therapy in Chronic Hepatitis B Patients with rt204I/V Mutation: a 96-Week Prospective Multicenter Trial
AASLD LiverLearning®, Sae Hwan Lee, 144780
A randomized study comparing tenofovir dispoxil fumarate and entecavir hydrate in Japanese patients with treatment naïve chronic hepatitis B
AASLD LiverLearning®, Wataru Sugiura, 144781
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemo-embolization
AASLD LiverLearning®, Sun Hong Yoo, 144782
Nutritional Assessment Tools as Prognostic Tools in Cirrhotic Patients
AASLD LiverLearning®, Meri Koulentaki, 144538
Understanding the unmet need in Autoimmune Hepatitis - The United Kingdom AIH Study (UK-AIH)
AASLD LiverLearning®, Lin Lee Wong, 144539
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF), a Novel Immune-Modulating Biologic, in Autoimmune Hepatitis
AASLD LiverLearning®, Christopher O'Brien, 144540
Characterization Of Changes In FibroTest Values During Treatment With Tenofovir Alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) In Patients With CHB
AASLD LiverLearning®, Namiki Izumi, 144796
Liver stiffness and virologic outcomes after introducing tenofovir as part of antiretroviral therapy in lamivudine-experienced adults with HIV and hepatitis B virus (HBV) co-infection in Ghana: four-year follow up of the prospective HEPIK cohort
AASLD LiverLearning®, Alexander Stockdale, 144797
Analysis of the incidence of primary hepatocellular carcinoma in Japanese patients with hepatitis B virus infection stratified by primary liver cancer risk score at the start of Entecavir therapy
AASLD LiverLearning®, Yoshiyasu Karino, 144798
Vitamin D Deficiency is Associated with Progression to Cirrhosis and Decompensation in Patients with Autoimmune Hepatitis
AASLD LiverLearning®, Rahima Bhanji, 144554
UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis
AASLD LiverLearning®, Lin Lee Wong, 144555
Preliminary Results from TOPAZ-III, A Phase 3b Study Evaluating the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in Naive or Experienced Adults in Brazil with HCV Genotype 1 Infection and Advanced Fibrosis/Cirrhosis
AASLD LiverLearning®, Mário Pessôa, 144811
RNA-seq analysis identifies early gene signature associated with antifibrotic efficacy of dual combination therapy directed against lysyl oxidase-like 2 (LOXL2) and apoptosis signal-regulating kinase 1 (ASK1) in BALBc.Mdr2-/- mice
AASLD LiverLearning®, Yury Popov, 144556
The influence of clinical significant portal hypertension (stage Baveno 2) on safety, tolerability and efficacy of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin (PrOD+R) in a real-world large cohort of genotype 1b HCV liver cirrhosis patien
AASLD LiverLearning®, Anca Trifan, 144812
Predictors of Sustained Virological Response (SVR) after Direct Acting Antiviral (DAA) treatment for Hepatitis C: meta-analysis of 55 studies in 11,419 patients
AASLD LiverLearning®, Bryony Simmons, 144813
Efficacy and safety of ombitasvir/ritonavir/paritaprevir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
AASLD LiverLearning®, Taeang Arai, 144814
25(OH) D3 alleviate liver NK cytotoxicity in early but not in late fibrosis model of Balb/c mice due to modulations in vitamin D receptor
AASLD LiverLearning®, Johnny Amer, 144570
Advanced glycation end products and dysregulated RAGE/AGER1 induce proinflammatory and fibrogenic signaling in NASH via NOX4
AASLD LiverLearning®, Ali Dehnad, 144571
Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice
AASLD LiverLearning®, Pamela Belperio, 144827
Anti-fibrotic and anti-inflammatory effect of a novel LPA1 receptor antagonist, UD-009, in a mouse model of NASH.
AASLD LiverLearning®, Kenji Nishikawa, 144572
Current treatment options with direct acting antivirals in HCV genotype 3 infections - still room for improvement? Results from the German multicenter GECCO cohort.
AASLD LiverLearning®, Julian Schulze zur Wiesch, 144828
Effect of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection with RAV negative population; from real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144829
Low hepatocelluar carcinoma (HCC) risk in HCV infected patients with liver cirrhosis or bridging fibrosis treated with different SOF-based DAA regimens: a single centre experience with a mean follow up of 12 months
AASLD LiverLearning®, Alessandra Mangia, 144830
Hepatic stellate cell Yes-associated protein 1 (Yap1) is necessary for liver regeneration
AASLD LiverLearning®, Anna Mae Diehl, 144586
Disruption of Heat Shock Transcription Factor 1 (HSF1) reveals its essential role in protection from liver inflammation and fibrosis
AASLD LiverLearning®, Asmita Choudhury, 144587
Use of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients with Advanced Chronic Kidney Disease (eGFR ≤ 30ml/min): A Case Series
AASLD LiverLearning®, Thomas McQuaid, 144843
Caveolin-1 targets lipid droplets formation in human hepatic stellate cells
AASLD LiverLearning®, Hiroaki Yokomori, 144588
Regression of liver fibrosis following Sustained Viral response (SVR) with Interferon(IFN)-free HCV treatment
AASLD LiverLearning®, Barbara Menzaghi, 144844
The impact of IL28B polymorphism and HCV NS5A resistance associated variants on treatment response with ledipasvir and sofosbuvir regimen in Japanese real-life settings
AASLD LiverLearning®, Hitomi Sezaki, 144845
Uptake of HCV Therapy in HIV/HCV Coinfected Patients across Europe in the Era of Direct-Acting Antivirals
AASLD LiverLearning®, Lars Peters, 144846
MELD-HE score: a new model to predict risk of mortality in variceal bleeding
AASLD LiverLearning®, Marika Rudler, 144602
Endoscopic Screening for large varices: increase in MELD score more predictive of variceal growth than calendar year
AASLD LiverLearning®, Sakkarin Chirapongsathorn, 144603
Efficacy and tolerability of IFN-free direct acting antivirals therapy (daclatasvir and asunaprevir) in chronic hemodialysis patients with chronic hepatitis C
AASLD LiverLearning®, Goki Suda, 144859
The comparison of long-term survival in cirrhotic patients with significant ascites and esophageal varices according to the treatment modality between endoscopic variceal ligation and non-selective beta-blockers
AASLD LiverLearning®, Jeong-Ju Yoo, 144604
Premature Discontinuation of Direct Acting Antiviral (DAA) Therapy in Patients with Chronic Hepatitis C Virus (HCV) in Real World Clinical Practice
AASLD LiverLearning®, Jasmine Hanifi, 144860
Sofosbuvir plus Ribavirin for difficult to treat HCV-2 : improved efficacy with extended treatment duration
AASLD LiverLearning®, Sara Piovesan, 144861
Efficacy and safety of the currently recommended regimens with direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, George Papatheodoridis, 144862
Comparing the Inpatient Disease Burden of HCV and HIV Infections: Trends in Hospitalization, Cost of Care, and Length of Stay
AASLD LiverLearning®, George Cholankeril, 144618
Extensive Economic and Quality of Life Burden of Viral Hepatitis (VH): The Data from the U.S. Medical Expenditure Panel Survey (MEPS)
AASLD LiverLearning®, Zobair Younossi, 144619
Difference of serum 4β-hydroxycholesterol level, a surrogate marker of CYP3A activity, among patients with chronic HCV infection
AASLD LiverLearning®, Tadashi Ikegami, 144875
Factors associated with survival in a population-based cohort of patients with end-stage liver disease
AASLD LiverLearning®, David Goldberg, 144620
Baseline and post-treatment hepatitis C NS5A resistance analysis in relapsed patients from a multicentric real life cohort of 2740 patients exposed to NS5A inhibitor
AASLD LiverLearning®, Philippe Halfon, 144876
Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: the Canadian National Experience.
AASLD LiverLearning®, Bandar Aljudaibi, 144877
Safety and efficacy of Interferon-free antiviral treatment in Hepatitis C patients with MELD score 20 and over
AASLD LiverLearning®, Carmen Vinaixa, 144878
Changes in liver biopsy training requirements to reflect competency-based medical education concepts
AASLD LiverLearning®, Oren Fix, 144634
Patient reported assessment of different diagnostic imaging tests for liver disease - visual representation and ownership of results improves understanding.
AASLD LiverLearning®, Andy McKay, 144635
Treatment Patterns Among Hepatitis C Virus Genotype 3 Patients in the United States
AASLD LiverLearning®, Lisa Rosenblatt, 144891
Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection
AASLD LiverLearning®, Brian McMahon, 144636
Factors that influence the improvement of liver albumin synthesis during interferon-free sofosbuvir-based therapy of chronic hepatitis C virus infection
AASLD LiverLearning®, Akira Kawano, 144892
Efficacy of direct-acting antiviral agents for treatment of HCV genotype 1 infection in Hispanics: data from a real-world cohort.
AASLD LiverLearning®, Andres Carrion, 144893
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials
AASLD LiverLearning®, Stefan Mauss, 144894